Elranatamab monotherapy in the real-word setting in relapsed-refractory multiple myeloma: results of the French compassionate use program on behalf of the IFM

Elranatamab is a humanized, bispecific antibody that targets B-cell maturation antigen (BCMA) on multiple myeloma (MM) cells and CD3 on T cells, with the aim of inducing T cell-mediated cytolysis of the MM cells [ 1 , 2 ]. Elranatamab was approved as monotherapy for relapsed-refractory MM (RRMM) based on the phase II MagnetisMM-3 (NCT04649359) registrational study [ 3 ]. Here, we report clinical outcomes with standard-of-care elranatamab in a real-world RRMM population as part of the French compassionate use program.